Common Contracts

EX-4 3 filename3.htm THIRD AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT

Stockholders’ Agreement • May 5th, 2020 • Delaware

• Contract Type
  Stockholders’ Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Delaware

This Third Amended and Restated Stockholders’ Agreement (this “Agreement”) is made and entered into as of April 27, 2016, by and among G1 Therapeutics, Inc., a Delaware corporation (the “Company”), the individuals and entities identified on Schedule A as the Series 1 Preferred Stockholders (the “Series 1 Preferred Stockholders”), the individuals and entities identified on Schedule A as the Series A Preferred Stockholders (the “Series A Preferred Stockholders”), the individuals and entities identified on Schedule A as the Series B Preferred Stockholders (the “Series B Preferred Stockholders”), the individuals and entities identified on Schedule A as the Series C Preferred Stockholders (the “Series C Preferred Stockholders”; the Series 1 Preferred Stockholders, the Series A Preferred Stockholders, the Series B Preferred Stockholders and the Series C Preferred Stockholders collectively, the “Investors” and each, an “Investor”), and the individuals or entities identified on Schedule A here

THIRD AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT

Stockholders’ Agreement • April 13th, 2017 • G1 Therapeutics, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Stockholders’ Agreement
• Filed
  April 13th, 2017
• Company
  G1 Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

This Third Amended and Restated Stockholders’ Agreement (this “Agreement”) is made and entered into as of April 27, 2016, by and among G1 Therapeutics, Inc., a Delaware corporation (the “Company”), the individuals and entities identified on Schedule A as the Series 1 Preferred Stockholders (the “Series 1 Preferred Stockholders”), the individuals and entities identified on Schedule A as the Series A Preferred Stockholders (the “Series A Preferred Stockholders”), the individuals and entities identified on Schedule A as the Series B Preferred Stockholders (the “Series B Preferred Stockholders”), the individuals and entities identified on Schedule A as the Series C Preferred Stockholders (the “Series C Preferred Stockholders”; the Series 1 Preferred Stockholders, the Series A Preferred Stockholders, the Series B Preferred Stockholders and the Series C Preferred Stockholders collectively, the “Investors” and each, an “Investor”), and the individuals or entities identified on Schedule A here